Clinical effect of therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod in treating Beh?觭et syndrome
WANG Yong1 HU Cuiping2 CHANG Junying1 NIU Yanyun3 DAI Pu4 GU Zhanqing1
1.Department of Rheumatology, Handan Hospital of Traditional Chinese Medicine, Hebei Province, Handan 056001, China;
2.No.2 Department of Encephalopathy, Handan Hospital of Traditional Chinese Medicine, Hebei Province, Handan 056001, China;
3.Department of Cardiopulmonary, Handan Hospital of Traditional Chinese Medicine, Hebei Province, Handan 056001, China;
4.Department of Internal Medicine, Jize County Hospital of Traditional Chinese Medicine, Hebei Province, Jize 057350, China
Abstract:Objective To explore the effect of therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod in treating Beh?觭et syndrome patients on the changes of inflammatory indices, clinical efficacy and safety. Methods From December 2015 to February 2017, 50 patients with Beh?觭et syndrome in Handan Hospital of Traditional Chinese Medicine were selected. They were divided into Chinese and Western medicine group 25 cases and Western medicine group 25 cases. Chinese and Western medicine group was given reduce phlegm and eliminate stasis decoction and Iguratimod Tablets, Western medicine group was given Iguratimod Tablets. Clinical efficacy, C reactive protein level, immunoglobulin A level, adverse reactions of medicine in the two groups were compared after 2 months′ treatment. Results After treatment, C reactive protein and immunoglobin A levels decreased than those before treatment (P < 0.01), the levels of C reactive protein and immunoglobulin A in the Chinese and Western medicine group were significantly lower than those in the western medicine group (P < 0.05). The clinical efficacy of the Chinese and Western medicine group was higher than the Western medicine group (P < 0.05); and adverse reactions rate in the Chinese and Western medicine group was lower than Western medicine group (P < 0.05). Conclusion Therapeutic regimen of reduce phlegm and eliminate stasis combined with Iguratimod can reduce Behcet syndrome patients′ C reactive protein and immunoglobulin A levels, improve clinical efficacy.